Today's Breaking News
- Dance Biopharm Presents Phase 2 Clinical Data Highlighting Rapid Effects of Inhaled Human Insulin at European Association for the Study of Diabetes Meeting
- Aptevo Therapeutics Introduces New Adaptir™ Bispecific Antibody Candidate Intended for the Treatment of Solid Tumors
- Y-Trap Enters Collaboration with Merck KGaA, Darmstadt, Germany, to Develop Novel Antibody-Ligand Traps for Immuno-Oncology
Latest R&D and Business News
- Allogene Therapeutics Enters Research Collaboration Directed at Enhancing Future Cancer Immunotherapies
- PDS Biotechnology Reports Clinical Data for Its Novel Immunotherapy PDS0101 in Follow up to Phase 1 Human Trial
- CinDome Pharma Announces Start of Phase 2 Trial of Deuterated Domperidone (CIN-102)
- Spruce Biosciences Announces Positive Results from 12-week, Phase 2a Study of Tildacerfont in Adults with Congenital Adrenal Hyperplasia
- 2019 CSCO | CStone announces promising trial data on its anti-PD-L1 antibody in esophageal squamous cell carcinoma with an ORR of 77.8%
- Phase 2 Study Published in Ophthalmology Highlights Efficacy and Safety Data of Intravitreal APL-2 for Geographic Atrophy Secondary to Age-Related Macular Degeneration
- STORM Therapeutics Presents Breakthrough Data Showing in Vivo Efficacy and Therapeutic Proof of Concept for Targeting RNA Modifying Enzymes
- Generium Launches First Biosimilar of Dornase Alfa; Becomes Sixth Approved Product Using Selexis SUREtechnology Platform
- U.S. FDA Approves Supplemental New Drug Application (sNDA) for ERLEADA® (apalutamide) for the Treatment of Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
- Procarta receives CARB-X award of up to $9.2 million
- Biogen Advances Spinal Muscular Atrophy (SMA) Clinical Research with New Study Evaluating a Higher Dose of SPINRAZA® (nusinersen) and Additional Data in a Broad Range of Patients
- Immunic, Inc. Doses First Healthy Volunteer in its Phase 1 Clinical Program of IMU-935, a Potentially Best-in-Class RORgt Inverse Agonist